Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915


Delayed Quote. Delayed Nasdaq Copenhagen - 10/15 10:59:44 am
658 DKK   +1.75%
10/14NOVO NORDISK : Buy rating from Goldman Sachs
10/12NOVO NORDISK A/S : Share repurchase programme - Form 6-K
10/05NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S : Matheson Advises Novo Nordisk A/S On The Purchase Of Neotope Neuroscience Limited

09/25/2021 | 02:09am EDT

Matheson recently advised Novo Nordisk A/S, a Danish multinational pharmaceutical company, alongside Davis Polk & Wardwell LLP, on its acquisition of Neotope Neuroscience Limited a wholly owned subsidiary of Prothena Corporation plc

Novo Nordisk A/S were advised by a cross-departmental Matheson team led by Corporate M&A partner David Fitzgibbon, Tax partner Aidan Fahy, Tax Principal John Ryan and Corporate senior associate John Coary.

Novo Nordisk A/S is a global healthcare company, founded in 1923 and headquartered in Denmark. Novo Nordisk employs more than 45,000 people in 80 offices around the world, and markets its products in 169 countries. 

The agreement between the two companies means that Novo Nordisk A/S has acquired Prothena's clinical stage antibody PRX004 and broader ATTR amyloidosis programme.

Under the terms of the agreement, Novo Nordisk A/S acquires full worldwide rights to the intellectual property and related rights of Prothena's ATTR amyloidosis business and pipeline. Prothena is eligible to receive development and sales milestone payments up to US$1.2 billion, including US$100 million dollars upfront and near-term clinical payments. On completion of the agreement, Novo Nordisk intends to initially focus on the clinical development of PRX004 in ATTR cardiomyopathy. 

David Fitzgibbon, Matheson corporate partner commented:

"We were very pleased to have advised Novo Nordisk on this  exciting acquisition. Novo Nordisk is a global leader in the pharmaceutical sector and we are delighted to have worked with their team to extend Novo Nordisk's commitment to bring therapies to market within the cardiovascular disease area.. We have recently advised on a number of clinical stage therapy acquisitions and only see this market continuing to expand both domestically and globally."

Aidan Fahy, Matheson tax partner commented:

"We were delighted to assist in making this a smooth and tax-efficient acquisition for them. By assisting in early planning and structuring of deals of this nature, we have a history of consistently being able to provide value for our clients and maximise returns for key stakeholders."

With a wealth of experience across our six partner led offices worldwide and a dedicated 100 person Corporate Department, Matheson has some of the most experienced corporate lawyers in Ireland.  Excellence matters and Matheson's Corporate Department, led by 23 partners, has unparalleled experience in complex and innovative domestic and international corporate transactions across all industry sectors.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mr David Fitzgibbon
70 Sir John Rogerson's Quay
Dublin 2
Tel: 1232 2101
Fax: 1232 3333
E-mail: Lisa.McLoughlin@matheson.com
URL: www.matheson.com/

© Mondaq Ltd, 2021 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

Stocks mentioned in the article
ChangeLast1st jan.
NOVO NORDISK A/S 1.75% 658 Delayed Quote.54.22%
PROTHENA CORPORATION PLC -2.31% 63.46 Delayed Quote.428.39%
All news about NOVO NORDISK A/S
10/14NOVO NORDISK : Buy rating from Goldman Sachs
10/12NOVO NORDISK A/S : Share repurchase programme - Form 6-K
10/05NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
10/05Xeris Pharmaceuticals, Inc. completed the acquisition of Strongbridge Biopharma plc fro..
10/04NOVO NORDISK A/S : – Share repurchase programme
09/28NOVO NORDISK : JP Morgan reiterates its Buy rating
09/27GLOBAL MARKETS LIVE : Intel, Apple, Rolls-Royce, Raytheon, MGM...
09/27NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
09/27BIOCORP : To Develop Add-On Device For Novo Nordisk's Insulin Pen
09/27Biocorp and Novo Nordisk Sign Global Partnership Within Diabetes on Digital Health
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Sales 2021 137 B 21 433 M 21 433 M
Net income 2021 46 458 M 7 247 M 7 247 M
Net cash 2021 6 428 M 1 003 M 1 003 M
P/E ratio 2021 32,6x
Yield 2021 1,51%
Capitalization 1 506 B 235 B 235 B
EV / Sales 2021 10,9x
EV / Sales 2022 9,91x
Nbr of Employees 45 971
Free-Float 69,8%
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 27
Last Close Price 658,00 DKK
Average target price 611,24 DKK
Spread / Average Target -7,11%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S54.22%234 792
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
PFIZER, INC.13.20%232 621
MERCK & CO., INC.-4.24%198 283